Purple Biotech Ltd
PPBT
$2.30
$0.0251.10%
NASDAQ
| 06/30/2025 | 12/31/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | 63.33% | 63.33% | |
| Gross Profit | -- | -- | -63.33% | -63.33% | |
| SG&A Expenses | -- | -- | -37.14% | -28.90% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -- | -- | -9.48% | 6.69% | |
| Operating Income | -- | -- | 9.48% | -6.69% | |
| Income Before Tax | -- | -- | 23.12% | 2.54% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -- | -- | 23.12% | 2.54% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -24.04% | -7.14% | |
| Net Income | -- | -- | 23.12% | 2.52% | |
| EBIT | -- | -- | 9.48% | -6.69% | |
| EBITDA | -- | -- | 9.40% | -6.93% | |
| EPS Basic | -- | -- | 40.65% | 22.66% | |
| Normalized Basic EPS | -- | -- | 52.42% | 16.46% | |
| EPS Diluted | -- | -- | 40.46% | 22.47% | |
| Normalized Diluted EPS | -- | -- | 52.42% | 16.46% | |
| Average Basic Shares Outstanding | -- | -- | 32.29% | 28.89% | |
| Average Diluted Shares Outstanding | -- | -- | 32.29% | 28.89% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |